StockWatch
·

Privi Speciality Chemicals Ltd

BSE: 530117

P/L Snapshot

Q2 FY27 · standalone

vs Q1 FY27·vs Q2 FY26
Revenue
734.11
+19.3%+11.8%
Expenditure
574.17
+14.3%+10.0%
Net Profit
119.29
+41.6%+18.9%
OPM %
27.08%
+2.84pp-1.01pp

Shareholding

Pattern breakdown

P/L Trends

(in crores)

RevenueExpenditureNet Profit
0.00205.55411.10616.66822.21Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27Q2 FY27
Price Chart
Reports

Record Profit Masks a Revenue Shortfall

earnings · specialty chemicals · profit growth

Result verdictFollow-upQ2 FY2703 Nov 20266 minMetals & Mining

Record PAT but revenue growth trailing 20% target

profit growth · margin expansion · capacity ramp

TranscriptDeep diveQ2 FY2703 Nov 20266 minMetals & Mining

Privi Q2 FY27: Consolidated PAT +30% YoY to ₹117.5 Cr as margins expand, beats Street

margin expansion · pat beat · aroma chemicals

ResultsQ2 FY2729 Oct 20263 minMetals & Mining
Latest
Board Meeting29 Oct, 1:07 pm

Privi Q2 FY27: Consolidated PAT +30% YoY to ₹117.5 Cr as margins expand, beats Street

Privi Speciality Chemicals' consolidated results for the quarter ended September 30, 2026 (Q2 FY27) comfortably cleared the bar set by our pre-result preview. Revenue from operations came in at ₹760.45 Cr, above the previewed ₹680-710 Cr range and up 12.0% YoY (₹678.71 Cr) and 14.1% QoQ (₹666.22 Cr). Consolidated PAT of ₹117.53 Cr was up 30.3% YoY and 41.9% QoQ, well clear of the ₹82-92 Cr the preview flagged as on-plan — a clean beat on both lines, consistent with Motilal Oswal's pre-result Buy thesis built on the medium-term execution case. No exceptional or one-off items are disclosed in either the standalone or consolidated statements this quarter, so the growth is on a like-for-like basis. Margins did the heavy lifting behind the profit beat. Consolidated EBITDA margin (PBT adjusted for other income, finance cost and depreciation, over revenue from operations) worked out to ~26.3%, recovering sharply from Q1 FY27's ~22.9% and roughly matching the year-ago quarter's 26.8% — back near the >25% level management has guided it will sustain. Net profit margin (PAT over total income) expanded to ~15.2%, up from 13.3% a year ago and 12.2% last quarter. Standalone PAT of ₹119.3 Cr was broadly in line with the consolidated figure (~1.5% higher), so there's no material standalone-versus-consolidated divergence to flag. On guidance, management's medium-term target of ₹5,000 Cr revenue and ₹1,000+ Cr EBITDA within 3-4 years (20% CAGR) is only partly on track: this quarter's 12.0% YoY revenue growth trails the 20% CAGR pace, even as the ~26.3% EBITDA margin print is already running ahead of the "around 25%" margin guidance from the last call — margin delivery is ahead of plan while topline growth needs to accelerate to hit the multi-year target. The company did not issue an accompanying press release or MD&A commentary with this filing, so there is no fresh management quote to weigh against the numbers; the only qualitative colour this quarter comes from the board's other actions disclosed alongside the results — a first interim dividend of ₹5/share (record date November 4, 2026) and the October 27, 2026 shareholder approval of the NCLT-directed Scheme of Amalgamation. Going into Q3 FY27, the two threads to track are whether revenue growth reaccelerates toward the 20% CAGR guided pace — tied to the delayed Phase-1 capacity move from 48K to 54K MT originally targeted for September 2026 — and whether the current ~26% EBITDA margin holds as that capacity ramps, alongside the Phase-2 expansion to 66K MT by September 2027 backed by ₹850-900 Cr of planned capex.

29 Oct 2026, 01:07 pm

Corporate Events

DividendPRIVISCL
2026
4Nov

₹5 / share

BSE Filing ↗
Board MeetingPRIVISCL
2026
29Oct

Board Meeting

The Board of Directors considered and approved the Unaudited…

BSE Filing ↗
Board MeetingPRIVISCL
2026
27Oct

Board Meeting

A meeting of the equity shareholders of Privi Speciality Che…

BSE Filing ↗
Board MeetingPRIVISCL
2026
7Aug

Board Meeting

The 40th Annual General Meeting of the company will be held …

BSE Filing ↗
Board MeetingPRIVISCL
2026
30Jul

Board Meeting

The meeting of the Board of Directors is scheduled to consid…

BSE Filing ↗
Board MeetingPRIVISCL
2026
7Jul

Board Meeting

The 41st Annual General Meeting (AGM) of the Company will be…

BSE Filing ↗
Board MeetingPRIVISCL
2025
19Dec

Board Meeting

Consider and approve scheme of amalgmation

BSE Filing ↗
Board MeetingPRIVISCL
2025
1Aug

Board Meeting

Consideration and approval of Unaudited standalone and conso…

BSE Filing ↗
DividendPRIVISCL
2024
24Jul

₹2 / share

BSE Filing ↗
Board MeetingPRIVISCL
2024
24Jun

Board Meeting

Outcome of the Board Meeting

BSE Filing ↗
Board MeetingPRIVISCL
2024
2May

Board Meeting

Consider and approve Audited Financials, recommend dividend,…

BSE Filing ↗
Board MeetingPRIVISCL
2024
25Jan

Board Meeting

Consider and approve Unaudited Financial Results for the per…

BSE Filing ↗
Board MeetingPRIVISCL
2023
6Nov

Board Meeting

Consider and approve Un-audited Standalone and Consolidated …

BSE Filing ↗